Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Health Canada has issued multiple public advisories since 2023 on unauthorized injectable peptide products, with BPC-157 named explicitly on the list of seized substances in actions against Canlab Research, Prime Research, and other vendors
Categories Route Volume
With repair peptides, the risk of open-ended use is simpler
should help you decide which option deserves a clinical review, not force a one-size answer
Shipping times are estimates only and are not guaranteed
Putting the evidence side by side Here is the blunt comparison: AOD 9604: 2.6 kg weight loss in 12 weeks (best result), failed six clinical trials, development terminated Semaglutide: 15 to 17 percent body weight loss over 68 weeks, FDA approved, thousands of study participants, consistent results across multiple trials There is no way to frame this comparison that puts AOD 9604 on equal footing with semaglutide when it comes to clinical evidence
US$ 29.52
US$ 24.60
US$ 26.29
US$ 29.48
US$ 28.46
US$ 21.59
US$ 22.73
US$ 26.02
